Publications


Publications, Projects & Awards

Organized by program & group, as selected by each corresponding VHIO Principal Investigator

Please click on the corresponding programs below

Cellular Plasticity & Cancer Group

Imagen

Principal Investigator
María Abad

Post-Doctoral Fellow
Elena Senís

Graduate Students
Olga Boix
Emanuela Greco
Iñaki Merino

Student
Noé Crespo

PUBLICATIONS

  1. Abad M*, Hashimoto H, Zhou H, Morales MG, Chen B, Bassel-Duby R, and Olson EN*. Notch inhibition enhances cardiac reprogramming by increasing MEF2c transcriptional activity. Stem Cell Reports. 2017 Mar 14;8(3):548-560. * Co-corresponding author.
  2. Marión RM, Lopez-de Silanes I, Mosteiro L, Gamache B, Abad M, Guerra C, Megías D, Serrano M, and Blasco MA. Common telomere changes during in vivo reprogramming and early stages of tumorigenesis. Stem Cell Reports. 2017 Feb 14;8(2):460-475.
  3. Gómez-Cabello D, Checa-Rodriguez C, Abad M, Serrano M and Huertas P. CtIP specific roles during cell reprogramming have long term consequences in iPSC survival and fitness. Stem Cell Reports. 2017 Feb 14;8(2):432-445.

PROJECTS

  • Programa Estatal de I+D+i Orientada a los Retos de la Sociedad (Governmental Program of R&D oriented to Societal Challenges).
    Ref. number: SAF2015-69413-R
    Principal investigator: Maria Abad
    Funding agency: Spanish Ministry of Economy and Competitiveness (MINECO)
  • Ramón y Cajal Grant
    Ref. number: RYC-2013-14747
    Principal investigator: Maria Abad
    Funding agency: Spanish Ministry of Economy and Competitiveness (MINECO)
  • XII Fero Fellowship
    Principal investigator: Maria Abad
    Funding agency: Fero Foundation
  • AECC Barcelona Provincial Council Projects
    Principal investigator: Maria Abad
    Funding agency: AECC

AWARDS

  • XII Fero Fellowship
    Principal investigator: Maria Abad
    Funding agency: Fero Foundation
  • AECC Barcelona Provincial Council Projects
    Principal investigator: Maria Abad
    Funding agency: AECC
  • AECC postodoctoral fellowship to Elena Senís, PhD
    Principal investigator: Maria Abad
    Funding agency: AECC

Experimental Hematology Group

Imagen

Principal Investigator
Francesc Bosch

Translational Research Coordinator
Marta Crespo

Clinical Research Coordinator
Pau Abrisqueta

Phd Students
Sabela Bobillo
Júlia Carabia
Cecilia Carpio
Isabel Jiménez
Júlia Montoro
Guillermo Orti

Post-Doctoral Scientists
Juan Camilo Nieto
Bárbara Tazón

Technician
Lluis Puigdefàbregas

Hematologists/Lab specialists
Pere Barba
Adoración Blanco
Laura Gallur
Merche Gironella
Andrés López
Ana Marín
Bryan Merchan
Pavel Olivera
Margartia Ortega
Carlos Palacio
Verónica Pons
Gaël Roué
Olga Salamero
Amparo Santamaría
David Valcárcel

PUBLICATIONS

  1. New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. Scott DW; Abrisqueta P; Wright GW; Slack GW; Mottok A; Villa D; Jares P; Rauert-Wunderlich H; Royo C; Clot G; Pinyol M; Boyle M; Chan FC; Braziel RM; Chan WC; Weisenburger DD; Cook JR; Greiner TC; Fu K; Ott G; Delabie J; Smeland EB; Holte H; Jaffe ES; Steidl C; Connors JM; Gascoyne RD; Rosenwald A; Staudt LM; Campo E; Rimsza LM; Lymphoma/Leukemia Molecular Profiling Project. 2017.J Clin Oncol.35: 1668-1677.
  2. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. Vitolo U; Trnený M; Belada D; Burke JM; Carella AM; Chua N; Abrisqueta P; Demeter J; Flinn I; Hong X; Kim WS; Pinto A; Shi YK; Tatsumi Y; Oestergaard MZ; Wenger M; Fingerle-Rowson G; Catalani O; Nielsen T; Martelli M; Sehn LH. 2017.J Clin Oncol.35: 3529-3537.
  3. Observation as the initial management strategy in patients with mantle cell lymphoma. Abrisqueta P; Scott DW; Slack GW; Steidl C; Mottok A; Gascoyne RD; Connors JM; Sehn LH; Savage KJ; Gerrie AS; Villa D. 2017.Ann Oncol.28: 2489-2495.
  4. A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts.Garcia-Manero G; Sekeres MA; Egyed M; Breccia M; Graux C; Cavenagh JD; Salman H; Illes A; Fenaux P; DeAngelo DJ; Stauder R; Yee K; Zhu N; Lee JH; Valcarcel D; MacWhannell A; Borbenyi Z; Gazi L; Acharyya S; Ide S; Marker M; Ottmann OG. 2017.Leukemia.31: 2799-2806.
  5. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea. Alvarez-Larrán A; Pérez-Encinas M; Ferrer-Marín F; Hernández-Boluda JC; Ramírez MJ; Martínez-López J; Magro E; Cruz Y; Mata MI; Aragües P; Fox ML; Cuevas B; Montesdeoca S; Hernández-Rivas JA; García-Gutiérrez V; Gómez-Casares MT; Steegmann JL; Durán MA; Gómez M; Kerguelen A; Bárez A; García MC; Boqué C; Raya JM; Martínez C; Albors M; García F; Burgaleta C; Besses C; Grupo Español de Neoplasias Mieloproliferativas Filadelfia Negativas. 2017.HAEMATOLOGICA.102: 103-109.
  6. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling. Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF. 2017.HAEMATOLOGICA.102: 1776-1784.
  7. The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κBmutational status. Vidal-Crespo A; Rodriguez V; Matas-Cespedes A; Lee E; Rivas-Delgado A; Giné E; Navarro A; Beà S; Campo E; López-Guillermo A; Lopez-Guerra M; Roué G; Colomer D; Pérez-Galán P. 2017.HAEMATOLOGICA.
  8. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Fink AM; Bahlo J; Robrecht S; Al-Sawaf O; Aldaoud A; Hebart H; Jentsch-Ullrich K; Dörfel S; Fischer K; Wendtner CM; Nösslinger T; Ghia P; Bosch F; Kater AP; Döhner H; Kneba M; Kreuzer KA; Tausch E; Stilgenbauer S; Ritgen M; Böttcher S; Eichhorst B; Hallek M. 2017.LANCET HAEMATOL.4: 475-486.
  9. Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial. Aguilar-Guisado M; Espigado I; Martín-Peña A; Gudiol C; Royo-Cebrecos C; Falantes J; Vázquez-López L; Montero MI; Rosso-Fernández C; de la Luz Martino M; Parody R; González-Campos J; Garzón-López S; Calderón-Cabrera C; Barba P; Rodríguez N; Rovira M; Montero-Mateos E; Carratalá J; Pérez-Simón JA; Cisneros JM. 2017.LANCET HAEMATOL.
  10. Excess mortality in the myelodysplastic syndromes.Nomdedeu M; Pereira A; Ramos F; Valcárcel D; Costa D; Arnan M; Calvo X; Pomares H; Luño E; Díaz-Campelo M; Collado R; de Paz R; Falantes JF; Pedro C; Marco J; Oirtzabal I; Sánchez-García J; Tormo M; Cedena MT; Nomdedeu B; Sanz G; Spanish MDS Group. 2017.AM J HEMATOL.92: 149-154.
  11. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R). Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Blanco ML; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu M; Ferrer A; Sanz GF; Florensa L. 2017.AM J HEMATOL.92: 614-621.
  12. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells. Purroy N; Carabia J; Abrisqueta P; Egia L; Aguiló M; Carpio C; Palacio C; Crespo M; Bosch F. 2017.Oncotarget.8: 742-756.
  13. Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions. Puiggros, Anna; Collado, Rosa; Jose Calasanz, Maria; Ortega, Margarita; Ruiz-Xiville, Neus; Rivas-Delgado, Alfredo; Luno, Elisa; Gonzalez, Teresa; Navarro, Blanca; Garcia-Malo, MaDolores; Valiente, Alberto; Angel Hernandez, Jose; Teresa Ardanaz, Maria; Angeles Pinan, Maria; Laura Blanco, Maria; Hernandez-Sanchez, Maria; Batlle-Lopez, Ana; Salgado, Rocio; Salido, Marta; Ferrer, Ana; Abrisqueta, Pau; Gimeno, Eva; Abella, Eugenia; Ferra, Christelle; Jose Terol, Maria; Ortuno, Francisco; Costa, Dolors; Moreno, Carol; Carbonell, Felix; Bosch, Francesc; Delgado, Julio; Espinet, Blanca. 2017.Oncotarget.8: 54297-54303.
  14. Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34(+) Selected Grafts for Allogeneic Hematopoietic Cell Transplantation. Barba P; Ratan R; Cho C; Ceberio I; Hilden P; Devlin SM; Maloy MA; Barker JN; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Ponce DM; Sauter C; Tamari R; van den Brink MR; Young JW; O'Reilly RJ; Giralt SA; Perales MA. 2017.Biol Blood Marrow Transplant.23: 67-74.
  15. Ex Vivo CD34(+)-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic. Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response. Barba P; Hilden P; Devlin SM; Maloy M; Dierov D; Nieves J; Garrett MD; Sogani J; Cho C; Barker JN; Kernan NA; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Prockop S; Sauter C; Tamari R; van den Brink MR; Avecilla ST; Meagher R; O'Reilly RJ; Goldberg JD; Young JW; Giralt S; Perales MA; Ponce DM. 2017.Biol Blood Marrow Transplant.23: 452-458.
  16. Early and Long-Term Impaired T Lymphocyte Immune Reconstitution after Cord Blood Transplantation with Antithymocyte Globulin. Castillo N; García-Cadenas I; Barba P; Canals C; Díaz-Heredia C; Martino R; Ferrà C; Badell I; Elorza I; Sierra J; Valcárcel D; Querol S. 2017.Biol Blood Marrow Transplant.23: 491-497.
  17. Do Patients and Physicians Agree When They Assess Quality of Life? Barata A; Martino R; Gich I; García-Cadenas I; Abella E; Barba P; Briones J; Brunet S; Esquirol A; García-Pallarols F; Garrido A; Granell M; Martinez J; Mensa I; Novelli S; Sanchez-Blanco B; Valcárcel D; Sierra J. 2017.Biol Blood Marrow Transplant.23: 1005-1010.
  18. Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes. Gerds AT; Woo Ahn K; Hu ZH; Abdel-Azim H; Akpek G; Aljurf M; Ballen KK; Beitinjaneh A; Bacher U; Cahn JY; Chhabra S; Cutler C; Daly A; DeFilipp Z; Gale RP; Gergis U; Grunwald MR; Hale GA; Hamilton BK; Jagasia M; Kamble RT; Kindwall-Keller T; Nishihori T; Olsson RF; Ramanathan M; Saad AA; Solh M; Ustun C; Valcárcel D; Warlick E; Wirk BM; Kalaycio M; Alyea E; Popat U; Sobecks R; Saber W. 2017.Biol Blood Marrow Transplant.23: 971-979.
  19. A Time-to-Event Model for Acute Kidney Injury after Reduced-Intensity Conditioning Stem Cell Transplantation Using a Tacrolimus- and Sirolimus-based Graft-versus-Host Disease Prophylaxis. Piñana JL; Perez-Pitarch A; Garcia-Cadenas I; Barba P; Hernandez-Boluda JC; Esquirol A; Fox ML; Terol MJ; Queraltó JM; Vima J; Valcarcel D; Ferriols-Lisart R; Sierra J; Solano C; Martino R. 2017.Biol Blood Marrow Transplant.23: 1177-1185.
  20. Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure. Jiménez-Ubieto A; Grande C; Caballero D; Yáñez L; Novelli S; Hernández-Garcia MT; Manzanares M; Arranz R; Ferreiro JJ; Bobillo S; Mercadal S; Galeo A; López Jiménez J; Moraleda JM; Vallejo C; Albo C; Pérez E; Marrero C; Magnano L; Palomera L; Jarque I; Martínez-Sánchez P; Martín A; Coria E; López-Guillermo A; Salar A; Lahuerta JJ. 2017.Biol Blood Marrow Transplant.23: 1631-1640.
  21. Efficacy of ß-Lactam/ß-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-ß-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia. Gudiol C; Royo-Cebrecos C; Abdala E; Akova M; Álvarez R; Maestro-de la Calle G; Cano A; Cervera C; Clemente WT; Martín-Dávila P; Freifeld A; Gómez L; Gottlieb T; Gurguí M; Herrera F; Manzur A; Maschmeyer G; Meije Y; Montejo M; Peghin M; Rodríguez-Baño J; Ruiz-Camps I; Sukiennik TC; Tebe C; Carratalà J; BICAR Study Group. 2017.Antimicrob Agents Chemother.
  22. Microenvironment regulates the expression of miR-21 and tumor suppressor genes PTEN, PIAS3 and PDCD4 through ZAP-70 in chronic lymphocytic leukemia. Carabia J; Carpio C; Abrisqueta P; Jiménez I; Purroy N; Calpe E; Palacio C; Bosch F; Crespo M. 2017.Sci Rep.7: 12262-0.
  23. Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells. Body S; Esteve-Arenys A; Miloudi H; Recasens-Zorzo C; Tchakarska G; Moros A; Bustany S; Vidal-Crespo A; Rodriguez V; Lavigne R; Com E; Casanova I; Mangues R; Weigert O; Sanjuan-Pla A; Menéndez P; Marcq B; Picquenot JM; Pérez-Galán P; Jardin F; Roué G; Sola B. 2017.Sci Rep.7: 13946-0.
  24. Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease. García-Cadenas I; Rivera I; Martino R; Esquirol A; Barba P; Novelli S; Orti G; Briones J; Brunet S; Valcarcel D; Sierra J. 2017.Bone Marrow Transplant.52: 107-113.
  25. Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation. Kharfan-Dabaja MA; Parody R; Perkins J; Lopez-Godino O; Lopez-Corral L; Vazquez L; Caballero D; Falantes J; Shapiro J; Ortí G; Barba P; Valcárcel D; Esquirol A; Martino R; Piñana JL; Solano C; Tsalatsanis A; Pidala J; Anasetti C; Perez-Simón JA. 2017.Bone Marrow Transplant.52: 438-444.
  26. Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis. Cho C; Hsu M; Barba P; Maloy MA; Avecilla ST; Barker JN; Castro-Malaspina H; Giralt SA; Jakubowski AA; Koehne G; Meagher RC; O'Reilly RJ; Papadopoulos EB; Ponce DM; Tamari R; van den Brink MRM; Young JW; Devlin SM; Perales MA. 2017.Bone Marrow Transplant.52: 1629-1636.
  27. An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase..Steegmann JL; Colomer D; Gómez-Casares MT; García-Gutiérrez V; Ortí G; Ramírez-Payer A; Olavarria E; Vall-Llovera F; Giraldo P; Conde E; Vallansot R; López-Lorenzo JL; Palomera L; Álvarez-Larrán A; Conesa V; Bautista G; Casas L; Giles F; Hochhaus A; Casado-Montero LF. 2017.J Cancer Res Clin Oncol.143: 2059-2066.
  28. Progression-free survival at 2 years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma. Jiménez-Ubieto A; Grande C; Caballero D; Yáñez L; Novelli S; Hernández MT; Manzanares M; Arranz R; Ferreiro JJ; Bobillo S; Mercadal S; Galego A; Jiménez JL; Moraleda JM; Vallejo C; Albo C; Pérez E; Marrero C; Magnano L; Palomera L; Jarque I; Coria E; Rodriguez A; Martín A; López-Guillermo A; Salar A; Lahuerta JJ; GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) cooperative stu. 2017.Cancer Med.6: 2766-2774.
  29. Calreticulin mutations are exceedingly rare in patients with myelodysplastic syndromes with myelofibrosis. Montoro J; Robledo C; Zamora L; Valcárcel D; Ramos F. 2017.ANN HEMATOL.96: 317-318.
  30. Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance. de Swart L; Smith A; MacKenzie M; Symeonidis A; Neukirchen J; Mikulenková D; Vallespí T; Zini G; Paszkowska-Kowalewska M; Kruger A; Saft L; Fenaux P; Bowen D; Hellström-Lindberg E; Cermák J; Stauder R; Tatic A; Holm MS; Malcovati L; Madry K; Droste J; Blijlevens N; de Witte T; Germing U. 2017.ANN HEMATOL.96: 1105-1112.
  31. Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid. Sanchez R; Ayala R; Alonso RA; Martínez MP; Ribera J; García O; Sanchez-Pina J; Mercadal S; Montesinos P; Martino R; Barba P; González-Campos J; Barrios M; Lavilla E; Gil C; Bernal T; Escoda L; Abella E; Amigo ML; Moreno MJ; Bravo P; Guàrdia R; Hernández-Rivas JM; García-Guiñón A; Piernas S; Ribera JM; Martínez-López J. 2017.ANN HEMATOL.96: 1069-1075.
  32. Prophylaxis with enoxaparin for prevention of venous thromboembolism after lung transplantation: a retrospective study. Sáez-Giménez B; Berastegui C; Sintes H; Perez-Miranda J; Figueredo A; López Meseguer M; Monforte V; Bravo C; Santamaría A; Ramon MA; Gómez-Ollés S; Roman A. 2017.TRANSPL INT.30: 1266-1274.
  33. Further psychometric validation of the GAH scale: Responsiveness and effect size. Cruz-Jentoft AJ; González B; de la Rubia J; Hernández Rivas JÁ; Soler JA; Fernández Lago C; Arnao M; Gironella M; Pérez Persona E; Zudaire MT; Olivier C; Altés A; García Guiñón A; Nomdedeu B; Arnan M; Ramírez Payer Á; Sánchez-Godoy P; Pajuelo N; Vilanova D; Monjil DF; Bonanad S; GAH Group. 2017.J GERIATR ONCOL.8: 211-215.
  34. Donor lymphocyte infusions in AML and MDS: Enhancing the graft-versus-leukemia effect. Orti G; Barba P; Fox L; Salamero O; Bosch F; Valcarcel D. 2017.EXP HEMATOL.48: 1-11.
  35. Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. Motlló C; Ribera JM; Morgades M; Granada I; Montesinos P; Brunet S; Bergua J; Tormo M; García-Boyero R; Sarrà J; Del Potro E; Grande C; Barba P; Bernal T; Amigo ML; Grau J; Cervera J; Feliu E; PETHEMA Group, Spanish Society of Hematology. 2017.Leuk Lymphoma.58: 145-152.
  36. Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis. Hernández-Boluda JC; Correa JG; García-Delgado R; Martínez-López J; Alvarez-Larrán A; Fox ML; García-Gutiérrez V; Pérez-Encinas M; Ferrer-Marín F; Mata-Vázquez MI; Raya JM; Estrada N; García S; Kerguelen A; Durán MA; Albors M; Cervantes F. 2017.EUR J HAEMATOL.98: 407-414.
  37. Spuriously low pulse oximetry saturation associated with hemoglobin Sydney in a child and relatives: Identification of this unstable hemoglobin may avoid unnecessary testing and hospital admissions..de Sevilla MF; Català A; Rives S; Berrueco R; Vidiella N; Camós M; Torrebadell M; Alonso-Saladrigues A; Mesegué M; Ruiz-Llobet A; Blanco-Álvarez A; Benéitez D. 2017.PEDIATR BLOOD CANCER.
  38. Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group..Nomdedeu M; Pereira A; Calvo X; Colomer J; Sole F; Arias A; Gomez C; Luño E; Cervera J; Arnan M; Pomares H; Ramos F; Oiartzabal I; Espinet B; Pedro C; Arrizabalaga B; Blanco ML; Tormo M; Hernandez-Rivas JM; Díez-Campelo M; Ortega M; Valcárcel D; Cedena MT; Collado R; Grau J; Granada I; Sanz G; Campo E; Esteve J; Costa D; Spanish MDS Group. 2017.Leuk Res.63: 85-89.
  39. Clinical efficacy of ß-lactam/ß-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum ß-lactamase-producing Enterobacteriaceae in haematological patients with neutropaenia: a study protocol for a retrospective observational study (BICAR). Gudiol C; Royo-Cebrecos C; Tebe C; Abdala E; Akova M; Álvarez R; Maestro-de la Calle G; Cano A; Cervera C; Clemente WT; Martín-Dávila P; Freifeld A; Gómez L; Gottlieb T; Gurguí M; Herrera F; Manzur A; Maschmeyer G; Meije Y; Montejo M; Peghin M; Rodríguez-Baño J; Ruiz-Camps I; Sukiennik TC; Carratalà J; BICAR study group. 2017.BMJ OPEN.
  40. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. Hidalgo M; Álvarez R; Gallego J; Guillén-Ponce C; Laquente B; Macarulla T; Muñoz A; Salgado M; Vera R; Adeva J; Alés I; Arévalo S; Blázquez J; Calsina A; Carmona A; de Madaria E; Díaz R; Díez L; Fernández T; de Paredes BG; Gallardo ME; González I; Hernando O; Jiménez P; López A; López C; López-Ríos F; Martín E; Martínez J; Martínez A; Montans J; Pazo R; Plaza JC; Peiró I; Reina JJ; Sanjuanbenito A; Yaya R; Carrato A. 2017.Clin Transl Oncol.19: 667-681.
  41. Asparaginase use for the treatment of acute lymphoblastic leukemia..Barba P; Dapena JL; Montesinos P; Rives S. 2017.Med Clin (Barc).148: 225-231.
  42. Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia. García-Marco JA; Delgado J; Hernández-Rivas JA; Ramírez Payer Á; Loscertales Pueyo J; Jarque I; Abrisqueta P; Giraldo P; Martínez R; Yáñez L; Terol MJ; González M; Bosch F; en nombre del Grupo Español de Leucemia Linfocítica Crónica (GELLC). 2017.Med Clin (Barc).148: 3811-3819.
  43. Bridge therapy in patients under anticoagulation: Is it still the question? Santamaría A. 2017.Med Clin (Barc).149: 303-304.
  44. Analytical parameters and vital signs in patients subjected to dental extraction. Jané-Pallí E; Arranz-Obispo C; González-Navarro B; Murat J; Ayuso-Montero R; Rojas S; Santamaría A; Jané-Salas E; López-López J. 2017.J Clin Exp Dent.
  45. Single umbilical cord blood with or without CD34+ cells from a third-party donor in adults with leukemia. Sanz J; Kwon M; Bautista G; Sanz MA; Balsalobre P; Piñana JL; Solano C; Duarte R; Ferrá C; Lorenzo I; Martín C; Barba P; Pascual MJ; Martino R; Gayoso J; Buño I; Regidor C; de la Iglesia A; Montoro J; Díez-Martín JL; Sanz GF; Cabrera R. 2017.Blood Adv.1: 1047-1055.

PROJECTS

  • Leucemia linfática crónica: progresión de la enfermedad y microambiente tumoral
    PI: Francesc Bosch
    Funding Entity: ISCIII
    Duration: 2015 – 2017
  • Patogènesi i noves dianes moleculars en síndromes limfoproliferatives B
    PI: Marta Crespo
    Funding Entity: MINECO
    Duration: 2014 – 2017
  • Targeted therapy for acute myeloid leukemia: ex vivo testing under conditions mimicking the bone marrow microenvironment
    PI: Marta Crespo
    Funding Entity: AECC, Barcelona
    Duration: 2016 – 2017
  • General
    PI: Francesc Bosch Funding Entity: La Generalitat de CatalunyaDuration: 2014 - ongoing

Tumor Immunology & Immunotherapy Group

Imagen

Principal Investigator
Alena Gros

Post-Doctoral Fellow
Carlos Alberto Fajardo

Graduate Students
Andrea Garcia
Maria Lozano

Technicians
Daniela Grases
Alejandro Negro

PROJECTS

  • Grantor: Miguel Servet Tipo I.
    Title: Characterization of neoantigen-specific T cells and identification of predictive biomarkers of response in patients with MSI and MSI-like CRC treated with anti-PDL1.
  • Grantor: Insitituto de Salud Carlos III.
    Title:Identificación de antígenos tumorales no canónicos y análisis de su relevancia en la inmunoterapia del cáncer
  • Grantor: Asociación Española Contra el Cáncer (Lab AECC).
    Title:Identification of biomarkers of response to cancer immunotherapy in liquid biopsies.
  • Grantor:Asociación Española Contra el Cáncer (Ideas Semilla).
    Title:Identification of the personalized repertoire of immunogenic tumor rejection epitopes.
  • Grantor: EMD Serono (Grant for Oncology Innovation).
    Title: Personalized non-invasive T-cell therapies targeting the mutanome

Applied Genetics of Metastatic Cancer Group

Imagen

Junior Principal Investigator
Leticia De Mattos-Arruda

PUBLICATIONS

  • De Mattos-Arruda L. Liquid biopsy for HER2-positive breast cancer brain metastasis: the role of the cerebro-spinal fluid. ESMO Open. 2017 Oct 9;2(4):e000270.
  • Callari M, Sammut SJ, De Mattos-Arruda L, Bruna A, Rueda OM, Chin SF, Caldas C. Intersect-then-combine approach: improving the performance of somatic variant calling in whole exome sequencing data using multiple aligners and callers. Genome Med. 2017 Apr 18;9(1):35.
  • Ramon YCS, Capdevila C, Hernandez-Losa J, De Mattos-Arruda L, Ghosh A, Lorent J, Larsson O, Aasen T, Postovit L M, Topisirovic I. Cancer as an ecomolecular disease and a neoplastic consortium. Biochim Biophys Acta. 2017 Dec;1868(2):484-499.
  • Banerjee S, Califano R, Corral J, de Azambuja E, De Mattos-Arruda L, Guarneri V, Hutka M, Jordan K, Martinelli E, Mountzios G, Ozturk MA, Petrova M, Postel-Vinay S, Preusser M, Qvortrup C, Volkov MNM, Tabernero J, Olmos D, Strijbos MH. Professional Burnout in European Young Oncologists: Results of The European Society For Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey. Ann Oncol. 2017 Jul 1;28(7):1590-1596.
  • Aapro M, Astier A, Audisio R, Banks I, Bedossa P, Brain E, Cameron D, Casali P, Chiti A, De Mattos-Arruda L, Kelly D, Lacombe D, Nilsson PJ, Piccart M, Poortmans P, Riklund K, Saeter G, Schrappe M, Soffietti R, Travado L, van Poppel H, Wait S, Naredi P. Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paper. Eur J Cancer 2017;82:193-202.

PROJECTS

  • The integrated genomic and immune landscapes of lethal metastatic breast cancer.
  • Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases.

AWARDS

  • Leticia De Mattos-Arruda was appointed by the European Society for Medical Oncology(ESMO)as member of its Breast Cancer Faculty Group (2017-2021). The role of this group is to help ESMO deliver on its committed efforts aimed at promoting education across the globe.
  • Leticia was invited to join ESMO Open’s Editorial Board in the breast cancer field (2018-2019).
  • She has also served as an ad hoc expert member in breast cancer for the Advisory Board of the European Medicines Agency (EMA).
  • Leticia was selected and awarded as part of the 2017 ESMO Leaders Generation Program (click here).
  • Collaborative work with Carlos Caldas’ Group, Cancer Research UK (CRUK), in analysing the role of genomics, transcriptomics and the immune system in metastatic breast cancers.
Imagen

Figure: Leticia De Mattos-Arruda receiving a 2017 ESMO Leaders Generation Program Award, presented by Fortunato Ciardiello, now ESMO Past President (2018-2019).

Chromatin Dynamics in Cancer Group

Imagen

Principal Investigator
Sandra Peiró

Post-Doctoral Fellow
Gaetano Verde

PhD Students
Marc Cosin
Laura Pascual Reguant
Gemma Serra Bardenys

Technician
Jessica Querol Paños

PUBLICATIONS

  1. Mazzolini R, Gonzalez N, Garcia-Garijo A, Millanes-Romero A, Peiró S, Smith S, Garcia de Herreros A and Canudas S. Snail1 transcription factor controls telomere transcription and integrity. Nucleic Acids Res. 2017 Oct 20.
  2. Izquierdo-Bouldstridge A, Bustillos A, Bonet-Costa C, Aribau-Miralbés P, l García-Gomis D, Dabad M, Esteve-Codina A, Pascual-Reguant L, Peiró S, Esteller M, Murtha M, Millán-Ariño L, Jordan A. Histone H1 depletion triggers an interferon response in cancer cells via activation of heterochromatic repeats. Nucleic Acids Res. 2017 Nov 16;45(20):11622-11642.
  3. Verde G, Querol-Paños J, Cebrià-Costa JP, Pascual-Regu ant L, Serra-Bardenys G, Iturbide A and Peiró S. Lysine-Specific Histone Demethylases Contribute to Cellular Differentiation and Carcinogenesis. Epigenomes. 2017, 1(1), 4.

PROJECTS

  • Project title: Finding oxH3 readers
    Funding: Fundació MaratóTV3
    Duration: 2014 – 2017
    Principal Investigator: Sandra Peiró
  • Project title: Chromatin Structure in EMT
    Funding: Instituto de Salud Carlos III (Institute of Health Carlos III, ISCIII)
    Duration: 2016 – 2019
    Principal Investigator: Sandra Peiró
  • Project title: Molecular mechanisms of BET inhibition in Estrogen Receptor-Positive   Breast Cancer Cells Resistant to CDK4/6 Treatment   
    Funding: Zenith Epigenetics (ISCIII)
    Duration: 2017 – 2019
    Principal Investigator: Sandra Peiró

Prostate Cancer Translational Research Group

Imagen

Principal Investigator
Joaquin Mateo

PUBLICATIONS

  1. Mateo, J., Ganji, G., Lemech, C., Burris, H. A., Han, S.-W., Swales, K., et al.. A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research,2017; 23(19), 5981–5992
  2. Goodall, J*., Mateo, J.*, Yuan, W., Mossop, H., Porta, N., Miranda, S., et al. (2017). Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. Cancer Discovery, 7(9), 1006–1017. doi:10.1158/2159-8290.CD-17-0261
  3. Seed, W. Yuan, J. Mateo, S. Carreira, C. Bertan, M. Lambros, G. Boysen, R. Ferraldeschi, S. Miranda, I. Figueiredo, R. Riisnaes, M. Crespo, D. Nava Rodrigues, E. Talevich, D. Robinson, LaL.kshmi Kunju, Y Wu, R. Lonigro, S. Sandhu, A. Chinnayan, J. de Bono. Gene Copy Number Estimation From Targeted Next Generation Sequencing Of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification. Clinical Cancer Research, 2017;23(20):6070-6077
  4. Mateo J, Boysen G, Barbieri CE, Bryant HE, Castro E, Nelson PS, Olmos D, Pritchard CC, Rubin MA, de Bono JS. DNA repair in prostate cancer: biology and clinical implications. Eur Urol 2017; 71(3):417-425
  5. Massard C, MateoJ, Loriot Y, Pezaro C, Albiges L, Mehra N, Varga A, Bianchini D, Ryan CJ, Petrylak DP, Attard G, Shen L, Fizazi K, de Bono J. : Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. Annals of Oncology. 2017 Jan 1;28(1):90-95

PROJECTS

  • Grantor: PROSTATE CANCER FOUNDATION, Defining the Landscape and Clinical Relevance of ATM Defects in Lethal Prostate Cancer.
  • Grantor: Fundación SEOM, Caracterización del impacto funcional de mutaciones en genes de la reparación del DNA en pacientes con cáncer de próstata.

AWARDS

  • Beca FSEOM para retorno o intensificación de investigadores
  • ASCO Cancer Conquer Foundation Merit Award

Radiomics Group

Imagen

Principal Investigator
Raquel Perez-Lopez

PUBLICATIONS

  1. Perez-Lopez R, Roda D, Jimenez B, Brown J, Mateo J, Carreira S, Lopez J, Banerji U, Molife R, Koh DM, Kaye S, de Bono J, Tunariu N and Yap T. High Frequency of Radiological Differential Responses with Poly (ADP-ribose) Polymerase Inhibitor Therapy. Oncotarget. 2017 Nov 6;8(61):104430-104443.
  2. Perez-Lopez R, Nava Rodrigues D, Figueiredo I, Mateo J, Collins D, Koh DM, de Bono J, Tunariu N. Multi-Parametric Magnetic Resonance Imaging of Prostate Cancer Bone Disease: Correlation with Bone Biopsy Histological and Molecular Features. Investigative Radiology. Invest Radiol. 2017 Sep 12.
  3. Perez-Lopez R, Mateo J, Mossop H, Blackledge MD, Collins DJ, Rata M, Morgan VA, Macdonald A, Sandhu S, Lorente D, Rescigno P, Zafeiriou Z, Bianchini D, Porta N, Hall E, Leach MO, de Bono JS, Koh DM, Tunariu N. Diffusion-weighted Imaging as a Treatment Response Biomarker Evaluating Bone Metastases in Prostate Cancer: A Pilot Study. Radiology. 2017 Apr; 283(1):168-177.
  4. Goodall J, Mateo J, Yuan W, Mossop H, Porta N, Miranda S, Perez-Lopez R, Dolling D, Robinson DR, Sandhu S, Fowler G, Ebbs B, Flohr P, Seed G, Rodrigues DN, Boysen G, Bertan C, Atkin M, Clarke M, Crespo M, Figueiredo I, Riisnaes R, Sumanasuriya S, Rescigno P, Zafeiriou Z, Sharp A, Tunariu N, Bianchini D, Gillman A, Lord CJ, Hall E, Chinnaiyan AM, Carreira S, de Bono JS; TOPARP-A investigators. Circulating Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. Cancer Discov. 2017 Apr 27. pii: CD-17-0261.
  5. Bianchini D, Lorente D, Rescigno P, Zafeiriou Z, Psychopaida E, O'Sullivan H, Alaras M, Kolinsky M, Sumanasuriya S, Sousa Fontes M, Mateo J, Perez Lopez R, Tunariu N, Fotiadis N, Kumar P, Tree A, Van As N, Khoo V, Parker C, Eeles R, Thompson A, Dearnaley D, de Bono JS. Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital. Clin Genitourin Cancer. 2017 Apr 26.